GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergan Inc (FRA:AG4) » Definitions » Piotroski F-Score

Allergan (FRA:AG4) Piotroski F-Score : 0 (As of Jun. 21, 2024)


View and export this data going back to . Start your Free Trial

What is Allergan Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Allergan has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Allergan's Piotroski F-Score or its related term are showing as below:


Allergan Piotroski F-Score Historical Data

The historical data trend for Allergan's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergan Piotroski F-Score Chart

Allergan Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 8.00 9.00 6.00 8.00

Allergan Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 7.00 7.00 7.00 8.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec14) TTM:Last Year (Dec13) TTM:
Net Income was 186.028 + 307.059 + 242.5 + 435.669 = €1,171 Mil.
Cash Flow from Operations was 119.873 + 348.349 + 461.332 + 562.996 = €1,493 Mil.
Revenue was 1190.13 + 1372.051 + 1410.07 + 1549.415 = €5,522 Mil.
Gross Profit was 1042.277 + 1208.512 + 1249.748 + 1379.835 = €4,880 Mil.
Average Total Assets from the begining of this year (Dec13)
to the end of this year (Dec14) was
(7719.239 + 7750.705 + 8089.229 + 9037.141 + 10069.133) / 5 = €8533.0894 Mil.
Total Assets at the begining of this year (Dec13) was €7,719 Mil.
Long-Term Debt & Capital Lease Obligation was €1,691 Mil.
Total Current Assets was €5,573 Mil.
Total Current Liabilities was €1,263 Mil.
Net Income was 9.65 + 272.804 + 224.25 + 228.417 = €735 Mil.

Revenue was 1126.811 + 1211.057 + 1165.908 + 1229.612 = €4,733 Mil.
Gross Profit was 972.488 + 1060.139 + 1022.142 + 1080.254 = €4,135 Mil.
Average Total Assets from the begining of last year (Dec12)
to the end of last year (Dec13) was
(6994.627 + 7141.386 + 7333.65 + 7588.161 + 7719.239) / 5 = €7355.4126 Mil.
Total Assets at the begining of last year (Dec12) was €6,995 Mil.
Long-Term Debt & Capital Lease Obligation was €1,532 Mil.
Total Current Assets was €3,883 Mil.
Total Current Liabilities was €908 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Allergan's current Net Income (TTM) was 1,171. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Allergan's current Cash Flow from Operations (TTM) was 1,493. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec13)
=1171.256/7719.239
=0.15173206

ROA (Last Year)=Net Income/Total Assets (Dec12)
=735.121/6994.627
=0.10509796

Allergan's return on assets of this year was 0.15173206. Allergan's return on assets of last year was 0.10509796. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Allergan's current Net Income (TTM) was 1,171. Allergan's current Cash Flow from Operations (TTM) was 1,493. ==> 1,493 > 1,171 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec14)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec13 to Dec14
=1691.178/8533.0894
=0.19819059

Gearing (Last Year: Dec13)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec12 to Dec13
=1531.759/7355.4126
=0.20824923

Allergan's gearing of this year was 0.19819059. Allergan's gearing of last year was 0.20824923. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec14)=Total Current Assets/Total Current Liabilities
=5572.543/1262.97
=4.41225286

Current Ratio (Last Year: Dec13)=Total Current Assets/Total Current Liabilities
=3883.381/908.339
=4.27525516

Allergan's current ratio of this year was 4.41225286. Allergan's current ratio of last year was 4.27525516. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Allergan's number of shares in issue this year was 305.2. Allergan's number of shares in issue last year was 301.5. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4880.372/5521.666
=0.8838586

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4135.023/4733.388
=0.87358632

Allergan's gross margin of this year was 0.8838586. Allergan's gross margin of last year was 0.87358632. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec13)
=5521.666/7719.239
=0.71531222

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec12)
=4733.388/6994.627
=0.67671771

Allergan's asset turnover of this year was 0.71531222. Allergan's asset turnover of last year was 0.67671771. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Allergan has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Allergan  (FRA:AG4) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Allergan Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Allergan's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergan (FRA:AG4) Business Description

Traded in Other Exchanges
N/A
Address
Website
Allergan Inc incorporated in Delaware in 1977. It is a multi-specialty health care company. The Company is engaged in the developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products that enable people to live life to its full potential - to see more clearly, move more freely and express themselves more fully. It offers products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets in more than 100 countries around the world. It is also engaged in specialty pharmaceutical, biologic and medical device research and development. The Company's business segments are specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces pharmaceutical products, including: ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologics products. The medical devices segment produces medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders; and facial aesthetics products. The Company sells its products directly through its own sales subsidiaries in approximately 40 countries and, supplemented by independent distributors, in over 100 countries. Its products are sold to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies and medical practitioners. The Company also utilize distributors for its products in smaller international markets. The Company's competitors include Akorn, Inc., Alcon Laboratories, Inc./Novartis AG, Abbott Laboratories, Alimera Sciences, Inc., Bausch & Lomb, Inc., a division of Valeant, Genentech/Hoffmann La Roche AG, Merck & Co., Pfizer Inc., Regeneron Pharmaceuticals, Inc. and Santen Seiyaku. Mentor and Sientra, Inc., or Sientra, a partner of Silimed, LifeCell Corporation, CR Bard Inc. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations, including the U.S. Occupational Safety and Health Act, the U.S. Toxic Substances Control Act, the U.S. Resource Conservation and Recovery Act, Superfund Amendments and Reauthorization Act, Comprehensive Environmental Response, Compensation and Liability Act and other current and potential future federal, state or local regulations.

Allergan (FRA:AG4) Headlines

No Headlines